Page 65 - Sohini Das

Glenmark Pharma launches Ryaltris nasal spray for allergic rhintis in US

British drugmaker Hikma to distribute Ryaltris while Glenmark will manufacture it

Streamlining trade margins on drugs priced Rs 100 and above likely

Drugs for ailments like chronic kidney disease, some high end antibiotics, anti-virals (anti-infectives), as well as some cancer drugs are likely to be brought under trade margin rationalization first

Medical tourism is set to beat pre-Covid-19 levels in next two quarters

Meanwhile, traditional Indian medicine centers have once again started receiving patients from overseas

Pricing regulator closely watching prices of diabetes drug going off patent

Regulator looking to cap prices of Sitagliptin, Linagliptin and combinations

Clear spike in heart attack cases after Covid-19 outbreak, say doctors

In recent times, several young celebrities, from politics to music to films, have succumbed to sudden heart attacks

Rise of cosmetic dermatology space gets big pharma looking for buyouts

According to reports, Torrent Pharmaceuticals is set to sign a deal to acquire Curatio Healthcare, a maker of skincare products, for Rs 2100 crore.

Bayer brings kidney disease treatment drug to India at 1/15th US cost

Brand named Kerendia (finerenone) will cost Rs 97.5 per day as treatment cost in India

After Covid, now a mammoth vaccination drive for lumpy skin disease

Cattle are being vaccinated swiftly as the disease breaks out of its initial holds of Rajasthan and Gujarat and starts infecting buffaloes too

Dolo 650 maker says drug part of Covid treatment, denies 'freebie' charges

In paracetamol market, Dolo's share rose to 24% from 15% pre-Covid-19

Ethical Code to keep doctor, drugmaker nexus at bay not mandatory yet

The recent controversy following income tax raids on Micro Labs, makers of popular paracetamol brand Dolo, is likely to make things move in making the UCPMP

PharmEasy calls off its public offer; to go for rights issue instead

API Holdings, the parent company of PharmEasy, wrote to shareholders announcing withdrawal of DRHP

The pink of health: Trade generics now key growth driver for Cipla

Vertical witnesses 25% CAGR in 5 yrs

Centre proposes anti-dumping duty on China antibiotic drug ofloxacin

No impact on end consumer as prices are regulated

US ranitidine litigation unlikely to impact Indian pharma: Analysts

Sun Pharmaceuticals, Dr Reddy's Laboratories, Perrigo and Teva have agreed to a combined settlement of $5 mn with cancer patient Joseph Bayer

Serum Institute, other firms eye tie-ups to develop monkeypox vaccine

Indian Immunologicals, and Haffkine Research Institute also in the fray

Specialty drugs may push Sun Pharma's US biz beyond $2 bn by 2025

The share of specialty medicines in overall pharmaceutical spending has been consistently increasing over the past decade, from 22 per cent in 2011 to 39 per cent in 2021

SII may use Oxford Biomedica's plant to make malaria, flu vaccines

SII is building a future pandemic facility, which will have an annual capacity of 2 bn doses

Bharat Biotech says Phase 3 trial over, intranasal vaccine 'safe'

Seeks nod as both primary and precaution dose

Indian Covid vaccine makers eye regulator nod for universal boosters

Plans afoot to seek regulator nod for universal boosters

Mandatory mask rule, fines back in Delhi as Covid cases rise again

Sharp rise in test positivity rate in Delhi past few weeks; doctors say many admitted for other ailments testing Covid-positive; Mumbai also sees spurt in cases